Project Grant R21AI174034
Award Date
7/18/24
Completion Date
6/30/26
Dollars Obligated
$246K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University, doing business as Boston University Medical Campus, to characterize the burden, severity, and phenotypic presentation of post-tuberculosis lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in tuberculosis (TB) patients with and without HIV. The total award amount is...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute. The grant, titled "Mechanisms of Efficient Control of Mycobacterium Tuberculosis in the Lungs Prior to Granuloma," aims to develop novel vaccination strategies to contain the tuberculosis pandemic. The research will use cutting-edge techniques like single-cell RNA...
This federal Project Grant award, valued at $774,881, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop pro-apoptotic (cell death-inducing) drugs as host-directed therapies to shorten treatment for drug-susceptible and multi-drug resistant pulmonary tuberculosis (TB), as well as prevent post-TB lung disease. The project will leverage advanced in vivo imaging...
This federal Project Grant award of $769,925.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to investigate the role of lung alveolar macrophage (AM) ontogeny and metabolism in regulating the permissiveness of AMs to Mycobacterium tuberculosis (MTB) infection. The research will utilize immunology, metabolism, genomics, microbiology, novel mouse models, and human primary AMs to understand how...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The project aims to quantify pDC lung trafficking during MTB infection, identify the chemokine receptor required for pDC lung homing, and define pDC's contribution to MTB...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform the global landscape of tuberculosis (TB) research by accelerating the study of human TB tissue samples. The award, totaling $1,185,782, will provide user-requested services to the global TB research community, consisting of: (1) pathological, cellular, structural, and/or genetic analysis of resected...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $787,171 to develop a new class of anti-tuberculosis (TB) compounds. The award supports research to discover and optimize 1,2,4-triazole and pyrrolidine compounds that inhibit the growth of drug-resistant strains of Mycobacterium tuberculosis, the causative agent of TB. The research aims to understand the...
This federal Project Grant award of $447,009 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) categorize AM sensing abilities and defects using ex vivo and in vivo delivery of MTB-related pathogen associated molecular patterns (PAMPs),...
This federal Project Grant award, valued at $899,894 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research on understanding the interactions between macrophages, neutrophils, and HIV that contribute to tuberculosis (TB) disease progression. The key products and services to be delivered under this grant include: Defining the type I interferon (IFN) signaling and...
This $517,185 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a research project to characterize the immune response to tuberculosis (TB) using integrated single-cell genomics and ancestry-adjusted expression quantitative trait loci (eQTL) mapping. The project will analyze peripheral blood mononuclear cells (PBMCs) collected from 225 individuals across three critical TB disease states...